Richard C. Pasternak

TL;DR: The development of the present statement involved a process of partial adaptation of other guideline statements and reports and supplemental literature searches, which confirmed that aggressive comprehensive risk factor management improves survival, reduces recurrent events and the need for interventional procedures, and improves quality of life for patients with established coronary disease.

TL;DR: The Clinical Efficacy Assessment Subcommittee of the American College of Physicians–American Society of Internal Medicine acknowledges the scientific validity of this product as a background paper and as a review that captures the levels of evidence in the management of patients with chronic stable angina as of November 17, 2002.

TL;DR: The approaches described in this statement can be used for guidance at several levels of primary prevention; however, the statement does not attempt to specifically link risk assessment to treatment guidelines for particular risk factors, but provides critical background information that could be used in the development of new treatment guidelines.

TL;DR: In the wake of the reports of the Women’s Health Initiative and the Heart and Estrogen/Progestin Replacement Study, which unexpectedly showed that combination hormone therapy was associated with adverse CVD effects, there is a heightened need to critically review and document strategies to prevent CVD in women.